Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NW-301V and NW-301D in advanced solid tumors
NCT06484556Phase 1Recruiting
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of NW-301V and NW-301D in solid tumor (2 cohorts). Primary endpoint: Dose-limiting toxicity at 28 days. Started Jun 2024; status: recruiting.
02
Drugs
NW-301VNW-301D
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06484556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06484556.